Literature DB >> 20107160

Japan works to shorten "drug lag," boost trials of new drugs.

Gunjan Sinha.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20107160     DOI： 10.1093/jnci/djq017

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  6 in total

1.  Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?

Authors:  Hideki Maeda; Tatsuo Kurokawa
Journal:  Int J Clin Oncol       Date:  2015-04-03       Impact factor: 3.402

2.  Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries.

Authors:  Hideki Maeda; Tatsuo Kurokawa
Journal:  Invest New Drugs       Date:  2014-03-11       Impact factor: 3.850

3.  An international survey of physicians regarding clinical trials: a comparison between Kyoto University Hospital and Seoul National University Hospital.

Authors:  Toshiko Ito-Ihara; Jeong-Hwa Hong; Ock-Joo Kim; Eriko Sumi; Soo-Youn Kim; Shiro Tanaka; Keiichi Narita; Taichi Hatta; Eun-Kyung Choi; Kyu-Jin Choi; Takuya Miyagawa; Manabu Minami; Toshinori Murayama; Masayuki Yokode
Journal:  BMC Med Res Methodol       Date:  2013-10-25       Impact factor: 4.615

4.  Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.

Authors:  R Shimazawa; M Ikeda
Journal:  J Clin Pharm Ther       Date:  2014-01-10       Impact factor: 2.512

5.  Effectiveness and safety of an extended-release tablet of sodium valproate for the prophylactic treatment of migraine: Postmarketing surveillance in Japan.

Authors:  Takao Takeshima; Norihiro Suzuki; Yasuhiko Matsumori; Naoki Shimmoto; Yuji Kurihara; Ryoji Gunji; Fumihiko Sakai
Journal:  Neurol Clin Neurosci       Date:  2016-04-26

6.  Differences in Investigator-Initiated Trials between Japan and Other Countries: Analyses of Clinical Trials Sponsored by Academia and Government in the ClinicalTrials.gov Registry and in the Three Japanese Registries.

Authors:  Tatsuya Ito
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.